Literature DB >> 20175500

Dosimetric verification of IMAT delivery with a conventional EPID system and a commercial portal dose image prediction tool.

Mauro Iori1, Elisabetta Cagni, Marta Paiusco, Peter Munro, Alan E Nahum.   

Abstract

PURPOSE: The electronic portal imaging device (EPID) is a system for checking the patient setup; as a result of its integration with the linear accelerator and software customized for dosimetry, it is increasingly used for verification of the delivery of fixed-field intensity-modulated radiation therapy (IMRT). In order to extend such an approach to intensity-modulated arc therapy (IMAT), the combined use of an EPID system and a portal dose image prediction (PDIP) tool has been investigated.
METHODS: The dosimetric behavior of an EPID system, mechanically reinforced to maintain its positional stability during the accelerator gantry rotation, has been studied to assess its ability to measure portal dose distributions for IMAT treatment beams. In addition, the PDIP tool of a commercial treatment planning system, commonly used for static IMRT dosimetry, has been validated for simulating the PDIs of IMAT treatment fields. The method has been applied to the delivery verification of 23 treatment fields that were measured in their dual mode of IMRT and IMAT modalities.
RESULTS: The EPID system has proved to be appropriate for measuring the PDIs of IMAT fields; additionally the PDIP tool was able to simulate these accurately. The results are quite similar to those obtained for static IMRT treatment verification, although it was necessary to investigate the dependence of the EPID signal and of the accelerator monitor chamber response on variable dose rate.
CONCLUSIONS: Our initial tests indicate that the EPID system, together with the PDIP tool, is a suitable device for the verification of IMAT plan delivery; however, additional tests are necessary to confirm these results.

Entities:  

Mesh:

Year:  2010        PMID: 20175500     DOI: 10.1118/1.3271107

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  Evaluation of two-dimensional electronic portal imaging device using integrated images during volumetric modulated arc therapy for prostate cancer.

Authors:  Shoki Inui; Yoshihiro Ueda; Shunsuke Ono; Shingo Ohira; Masaru Isono; Yuya Nitta; Hikari Ueda; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

2.  Feasibility of a remote, automated daily delivery verification of volumetric-modulated arc therapy treatments using a commercial record and verify system.

Authors:  Jonas D Fontenot
Journal:  J Appl Clin Med Phys       Date:  2012-03-08       Impact factor: 2.102

3.  EPID dosimetry for pretreatment quality assurance with two commercial systems.

Authors:  Daniel W Bailey; Lalith Kumaraswamy; Mohammad Bakhtiari; Harish K Malhotra; Matthew B Podgorsak
Journal:  J Appl Clin Med Phys       Date:  2012-07-05       Impact factor: 2.102

4.  Gafchromic EBT-XD film: Dosimetry characterization in high-dose, volumetric-modulated arc therapy.

Authors:  Hideharu Miura; Shuichi Ozawa; Fumika Hosono; Naoki Sumida; Toshiya Okazue; Kiyoshi Yamada; Yasushi Nagata
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

5.  Comparison between an in-house 1D profile correction method and a 2D correction provided in Varian's PDPC Package for improving the accuracy of portal dosimetry images.

Authors:  Maritza A Hobson; Stephen D Davis
Journal:  J Appl Clin Med Phys       Date:  2015-03-08       Impact factor: 2.102

6.  Normalize the response of EPID in pursuit of linear accelerator dosimetry standardization.

Authors:  Bin Cai; S Murty Goddu; Sridhar Yaddanapudi; Douglas Caruthers; Jie Wen; Camille Noel; Sasa Mutic; Baozhou Sun
Journal:  J Appl Clin Med Phys       Date:  2017-11-10       Impact factor: 2.102

7.  Comparison of pretreatment VMAT quality assurance with the integral quality monitor (IQM) and electronic portal imaging device (EPID).

Authors:  Melissa Ghafarian; Michael Price; Manuel Morales-Paliza
Journal:  J Appl Clin Med Phys       Date:  2021-02-17       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.